Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + ruxolitinib
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy of two drugs: - **Paclitaxel** is an anti-mitotic chemotherapy agent that stabilizes microtubules and prevents their depolymerization. This disrupts cell division and induces apoptosis in cancer cells. It is widely used in the treatment of breast cancer and other solid tumors. - **Ruxolitinib** is an orally bioavailable small molecule inhibitor of Janus kinase 1 and 2 (JAK1/2). By inhibiting the JAK-STAT pathway—particularly JAK2-STAT3 signaling—it blocks cytokine-mediated cell proliferation and survival signals. Ruxolitinib has been approved for myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease. The combination has been investigated primarily in HER2-negative metastatic breast cancer—including triple-negative subtypes—and ovarian cancer. Preclinical studies suggest that JAK inhibition can sensitize tumor stem-like cells to chemotherapy by promoting apoptosis through STAT3 pathway inhibition[1][6][8]. Clinical trials have shown this regimen to be tolerable with evidence of clinical activity[1][2].
- Brand names
- Jakavi
- Other names
- TaxolINCB018242INCB-018242INCB 018242
02
Targets
Beyond the preview
Go deeper on paclitaxel + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + ruxolitinib.